Protein Supplementation and Mixed Power Training on Muscle Function and Functional Capacities in Elderly Men

NCT ID: NCT03393650

Last Updated: 2018-01-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-09-30

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Investigate the effect of 12 weeks mixed power training (power and functional exercises) combined with a protein supplementation (30g/d) or not (placebo) on physiological characteristics of muscle and functional capacities in elderly men.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Life habits are know to be able to prevent the loss of functional capacities and muscle function during aging process. More specifically, protein intake is important to maintain muscle function in older adults. Another non pharmacological intervention and well recognized for its efficacy, it's exercise training.

Recently, it has been observed than muscle quality is more important to maintain physical autonomy than muscle mass per se. In addition, muscle quality is more related to functional capacities than muscle mass.

Due to this recent finding, it has been proposed that muscle power training would be the best exercise intervention to prevent the loss of mobility.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dynapenia Aging Physical Impairment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Exercise + Placebo group

50 subjects will receive a placebo supplementation with an exercise intervention (EX group)

Group Type ACTIVE_COMPARATOR

Exercise + Placebo group

Intervention Type OTHER

1/2 of the subject will follow a mixed power training: 4 power exercises + 6 functional exercises combined to a placebo

Exercise + Protein group

50 subjects will receive a protein supplementation combined with an exercise intervention (PROTEX group)

Group Type ACTIVE_COMPARATOR

Exercise + Protein group

Intervention Type OTHER

1/2 of the subject will receive 30 g/ d of protein (leucine+ vitD; divided in three equal doses: morning, afternoon and evening) + will follow a mixed power training: 4 power exercises + 6 functional exercises.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Exercise + Placebo group

1/2 of the subject will follow a mixed power training: 4 power exercises + 6 functional exercises combined to a placebo

Intervention Type OTHER

Exercise + Protein group

1/2 of the subject will receive 30 g/ d of protein (leucine+ vitD; divided in three equal doses: morning, afternoon and evening) + will follow a mixed power training: 4 power exercises + 6 functional exercises.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Elderly men
* 60 years and older
* Sedentary men
* Not obese (BMI \<30 kg/m2)
* Living in free-living community

Exclusion Criteria

* Not able to follow an exercise program (doctor authorization: XAAP)
* Having Lactose intolerance
* Having Pace marker
* Having Metabolism disorder
* No weight stable since the last 6 months
* No stable medication (same dose and type since at least 6 months)
Minimum Eligible Age

60 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Université du Québec a Montréal

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mylène Aubertin-Leheudre

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

mylene aubertin-leheudre, PhD

Role: PRINCIPAL_INVESTIGATOR

Université du Québec a Montréal

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

UQAM

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.